Cas:178974-97-5 2,4-Difluoro-3-methoxybenzoic acid manufacturer & supplier

Chemical Name:2,4-Difluoro-3-methoxybenzoic acid

CAS.NO:178974-97-5

Synonyms:10535236;2,4-difluoro-3-methoxylbenzoic acid;MFCD02258905;2,4,6-TRICHLOROPHENYL 4-FLUOROBENZENESULFONATE;GVR BF DF CO1;2,4-Difluoro-m-anisic acid;3-Methoxy-2,4-difluorobenzoic acid;2,4-Difluoro-3-methoxybenzoic acid;Benzoic acid, 2,4-difluoro-3-methoxy-;2,4-Difluoro-3-methoxy benzoic acid

Molecular Formula:C₈H₆F₂O₃

Molecular Weight:188.128

HS Code:2918990090

Physical and Chemical Properties:

Melting point:193-195°C

Boiling point:298.7±35.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.505

PSA:46.53000

Exact Mass:188.028503

LogP:2.10

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 10535236 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Difluoro-3-methoxy benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Difluoro-3-methoxybenzoic acid Use and application,2,4-Difluoro-3-methoxy benzoic acid technical grade,usp/ep/jp grade.

Related News: APIs are generally manufactured through a variety of processes that include. 2,4-Difluoro-3-methoxybenzoic acid manufacturer Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 2,4-Difluoro-3-methoxybenzoic acid supplier Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. 2,4-Difluoro-3-methoxybenzoic acid vendor This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 2,4-Difluoro-3-methoxybenzoic acid factory Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer.